Akums Drugs and Pharmaceuticals has announced it will conduct a physical investor and analysts conference call on June 1, 2026. The meeting, designated as a group meet under the theme 'Rising Stars', is scheduled to begin at 09:00 AM IST at the Grand Hyatt in Mumbai. The intimation was submitted to the exchanges pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company stated that the decision process for the event took more time than anticipated, resulting in the late intimation regarding the schedule. Akums clarified that no unpublished price sensitive information pertaining to the company will be shared during the meet with analysts and investors. The schedule remains subject to change due to exigencies on the part of the host or the company.

Meeting Details

The following table outlines the specific particulars of the scheduled conference call:

Dharamvir Malik, Company Secretary & Compliance Officer, signed the disclosure on behalf of Akums Drugs and Pharmaceuticals Limited. A copy of the disclosure has been updated on the company's official website.

Akums Drugs and Pharmaceuticals and its subsidiaries have received assessment orders from the Income Tax Department. The orders were issued under Section 158BC of the Income Tax Act, 1961, covering the block period from April 1, 2018, to March 12, 2025. The total demand raised against the company and its subsidiaries amounts to ₹156.01 crore.

Details of the Assessment Orders

The Income Tax Department, Office of the Deputy Commissioner of Income Tax, Central Circle 1, New Delhi, passed the orders regarding the disallowance of various expenditures under Section 37(1) of the Income Tax Act. While the company and Akumentis Healthcare Ltd. received orders dated May 19 and May 20, 2026, respectively, four wholly-owned subsidiaries—Maxcure Nutravedics Limited, Pure and Cure Healthcare Private Limited, Malik Lifesciences Private Limited, and Nicholas Healthcare Limited—also received similar orders on May 21 and May 22, 2026.

Financial Impact and Response

The company stated that based on its internal assessment, it does not expect the orders to have a material financial impact. Management believes the demands are not sustainable in law and are defendable based on the facts of the case. Consequently, the entities plan to pursue appeals against the orders under applicable laws.